TTTsuyoshi Takagi

Tsuyoshi Takagi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tsuyoshi Takagi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Longitudinal plasma phosphorylated neurofilament-heavy chain levels in oxaliplatin-induced peripheral neuropathy: a prospective multi-institutional exploratory study

    by Yoshiharu Motoo, Katsunori Shinozaki, Masatomo Miura, Tsuyoshi Takagi, Shingo Ito, Naohisa Yoshida, Yoshinori Munemoto, Akihito Tsuji

    Purpose Reliable circulating biomarkers for chemotherapy-induced peripheral neuropathy (CIPN) remain lacking. Phosphorylated neurofilament-heavy chain (pNF-H) is an axon-oriented biomarker of neuroaxonal injury, but its clinical relevance in oxaliplatin-induced peripheral neuropathy has not been established. We evaluated the feasibility and longitudinal behavior of plasma pNF-H in patients receiving oxaliplatin-based chemotherapy. Methods This prospective multi-institutional exploratory study included patients with unresectable or recurrent colorectal cancer receiving CapeOX plus bevacizumab as part of the NYX study, a randomised trial of ninjin’yoeito (NYT; TJ-108, Tsumura & Co., Tokyo, Japan), a twelve-ingredient Kampo herbal extract, at 9.0 g/day for 24 weeks in the NYT arm. Plasma samples were collected at baseline, at clinically assessed CIPN onset (follow-up 1), and at the time of neuropathy resolution, at cycle 9, or at discontinuation, whichever came first (follow-up 2). Plasma pNF-H concentrations were measured by enzyme-linked immunosorbent assay. CIPN was assessed using CTCAE version 5.0. Results Thirty patients with evaluable plasma samples were included. Plasma pNF-H levels showed substantial inter-individual variability without a consistent temporal pattern. Compared with baseline and CIPN onset, plasma pNF-H levels at follow-up 2 were modestly but significantly increased. However, plasma pNF-H levels were not associated with the onset, severity, or persistence of clinically assessed CIPN. Conclusions Although longitudinal plasma pNF-H measurement was technically feasible, pNF-H did not function as a clinically meaningful biomarker for oxaliplatin-induced peripheral neuropathy. These findings may reflect a pathophysiological mismatch between dorsal root ganglion neuronal cell body injury and the axon-oriented biological specificity of pNF-H.

  • Open Access

    Randomized controlled trial of the significance of combined use with Ninjin’yoeito in CapeOX + Bmab therapy for patients with unresectable advanced/recurrent colorectal cancer

    by Yoshiharu Motoo, Katsunori Shinozaki, Tsuyoshi Takagi, Shingo Ito, Hideto Fujita, Yoshinori Munemoto, Naohisa Yoshida, Eishi Baba, Yoshiaki Shindo, Takamasa Nishiuchi, et al.

    Background: This randomized controlled trial is aimed at clarifying the benefit of an extract of ninjin’yoeito (NYT, traditional Japanese herbal medicine, Kampo) when combined with capecitabine plus oxaliplatin (CapeOX) plus bevacizumab (Bmab) in 150 patients with metastatic or recurrent colorectal cancer with special reference to nutritional status. Methods/Design: Patients with unresectable, metastatic, or recurrent colorectal cancer who plan to receive CapeOX + Bmab will be recruited. Of these patients, those who provide written informed consent will be randomly allocated to the NYT group (NYT + CapeOX + Bmab) or the control group (CapeOX + Bmab). The co-primary endpoints will be nutritional status, evaluated with CONtrolling NUTritional Status scores, and severe non-hematological adverse events, assessed using the Common Terminology Criteria for Adverse Events v5.0. The secondary endpoints will include the interaction between NYT and capecitabine; quality of life evaluated using the European Organization for Research and Treatment of Cancer-QLQ-C30; relative dose intensity of oxaliplatin, capecitabine, and bevacizumab; and plasma levels of phosphorylated neurofilament heavy chain. The two groups will include 75 patients each, and the patient recruitment period is January 1st, 2020 to December 31st, 2022. Discussion: This trial evaluates the efficacy and safety of NYT in the maintenance of a better nutritional status and fewer adverse events during the standard chemotherapeutic regimen of CapeOX + Bmab administered to patients with advanced or recurrent colorectal cancer. The potential implications include that NYT could be a strong supportive therapy in patients with colorectal cancer receiving chemotherapy. Trial registration number: This study was registered in the Japan Registry of Clinical Trials (registration number: jRCTs041190071) on October 2, 2019.


  • Open Access

    Prediction of Immediate Effectiveness in Conservative Treatment for Acute Appendicitis

    by Shoji Hirajima, Hiroki Kobayashi, Tsuyoshi Takagi, Kanehisa Fukumoto

    急性虫垂炎において保存的治療が奏効するかどうか,治療早期に判断できる指標を検討する. 当院で保存的治療を行った急性虫垂炎65例を検討した.65例中55例で保存的治療が有効であったが,10例は保存的治療が無効で即時手術を行った.保存的治療有効群55例中7例において,保存的治療が有効であったものの,入院期間が14日間を超え治療に難渋した.次に即時手術群10例に保存的治療が難渋した7例を加えた17例を,保存的治療が奏効した48例と比較した.年齢,糞石,膿瘍の有無,治療開始後のWBC,CRP値で差を認めた.これら因子を用いて,保存的治療が奏効するか否かの予測式を作成した.この予測式によって,保存的治療が奏効するか否かの感度は95.8%,特異度は88.2%であった. 急性虫垂炎に対して保存的治療が奏効するか否か,この予測式が1つの指標になると考える.

  • Open Access

    Mucinous Cystadenocarcinoma Arising in the Mesentery Proper—A Case Report—

    by Shoji Hirajima, Tsuyoshi Takagi, Hiroki Kobayashi, Kanehisa Fukumoto, Akio Yanagisawa

    症例は63歳,男性.上部直腸癌精査時のCTで,腸間膜に長径70mm大の不整形,内部に石灰化を伴い造影効果のある嚢胞性腫瘤を認めた.リンパ管腫,GISTを鑑別診断として,直腸癌手術と同時に嚢腫摘出術を施行した.嚢腫は終末回腸から130cm口側の小腸間膜に不整形の腫瘤として存在し,小腸との連続性は認めなかった.小腸間膜の血管を温存する格好で,完全切除は容易であった.摘出した嚢腫は80mm×45mm×25mmで,内部には黄色の粘液性物質と透明の漿液性物質が混在していた.病理検査で嚢腫壁に粘液を有する円柱上皮を認め,腸間膜粘液性嚢胞腺癌と診断された.腸間膜嚢腫は比較的まれな疾患であり,嚢腫に悪性所見を伴うことは極めてまれである.われわれは上部直腸癌術前に偶然発見された無症候性小腸腸間膜粘液性嚢胞腺癌を経験したので報告する.